Latest Design Source Inc (NVIV) Headlines InV
Post# of 58
Posted On: 03/10/2014 8:34:45 PM
Latest Design Source Inc (NVIV) Headlines
InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer
Business Wire - Mon Feb 24, 7:03AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced appointment of Thomas R. Ulich, MD as Chief Scientific Officer, effective February 24, 2014.
OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Holdings Corp sends amended protocol to FDA and six cllinical sites for approval
M2 - Mon Jan 06, 5:43AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) reported on Friday the submission of the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair to the US Food and Drug Administration.
InVivo Sends Amended Protocol to FDA and Six Clinical Sites
Business Wire - Fri Jan 03, 2:18PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has sent to the United States Food and Drug Administration the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair. The revised protocol includes all changes that were conditions of approval by the FDA. On Monday, it will send the revised protocol and related study documents to six sites in the United States so that they can now begin their Institutional Review Board submissions and finalize clinical study contracts with InVivo.
Novel Health Initiative for Walgreen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 5:20PM CST
Walgreen undertakes a novel initiative to help in the implementation of the Affordable Care Act.
InVivo Announces Regulatory and Clinical Promotions
Business Wire - Fri Dec 27, 8:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.
InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval
Business Wire - Thu Dec 26, 1:00PM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury. InVivo submitted these proposed changes to the FDA on November 21, 2013 and will follow the FDA's approval conditions in their entirety in a submission to the FDA next week.
InVivo Therapeutics Holdings Corp elects Mark Perrin as CEO
M2 - Tue Dec 24, 7:14AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (Other OTC:NVIV) reported on Monday the election of Mark D Perrin as its chief executive officer.
InVivo Names Mark Perrin as Its New Chief Executive Officer
Business Wire - Mon Dec 23, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chief Executive Officer, effective January 6, 2014. Upon his appointment, Mr. Perrin will also become a member of the Board of Directors.
OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp. (OTCQB: NVIV)
WorldStockWire - Wed Dec 18, 4:45AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Appoints Steven McAllister as Interim CFO
Business Wire - Mon Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Interim Chief Financial Officer, effective December 31, 2013. He replaces Gregory Perry, who, as previously announced, will leave December 30, 2013 to join another local biotechnology company as its Chief Financial and Business Officer.
InVivo Therapeutics Announces Promotions in Technical Operations
Business Wire - Mon Dec 09, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that William D'Agostino has been promoted to Vice President, Manufacturing & Engineering and Robert Ham has been promoted to Senior Director, Quality. These promotions are effective January 1, 2014.
InVivo Therapeutics names Christopher McNulty as VP, Business Development
M2 - Tue Nov 19, 4:05AM CST
InVivo Therapeutics Holdings Corp (OTC:NVIV), a biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, announced on Monday the appointment of Christopher McNulty as vice president, Business Development.
InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development
Business Wire - Mon Nov 18, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as Vice President, Business Development.
InVivo Therapeutics Lead Program on Track
Business Wire - Fri Nov 15, 10:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today confirmed that the company expects that the clinical trial of its first investigational product, a degradable polymer scaffold designed to promote healing following acute spinal cord injury, will be ready to enroll patients in the first quarter of 2014.
News and Updates on CTIX, CERP, NVIV and TRTC
ACCESSWIRE - Tue Nov 12, 12:31AM CST
News and updates on Cellceutix Corporation (OTC:CTIX), Cereplast Inc. (OTC:CERP), InVivo Therapeutics Holdings Corp. (OTC:NVIV) and Terra Tech Corp. (OTC:TRTC).
InVivo Therapeutics Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 07, 3:14PM CST
InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the three and nine months ended September 30, 2013.
Small Cap Equity Reports on NVIV, SCRC and WDDD
ACCESSWIRE - Mon Oct 28, 1:02AM CDT
InVivo Therapeutics Holdings Corp. (OTC: NVIV), ScripsAmerica, Inc. (OTC: SCRC) and Worlds Inc. (OTC: WDDD) are small cap stocks in focus.
InVivo Therapeutics Holdings Corp names Dr Lou Vaickus interim CMO
M2 - Fri Oct 11, 10:35AM CDT
Drug delivery company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) revealed on Friday the election of Dr Lou Vaickus, MD as its interim chief medical officer for one year commencing 15 October 2013.
InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical Officer
Business Wire - Fri Oct 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Lou Vaickus, MD has been appointed as interim Chief Medical Officer (CMO), effective October 15, 2013, for a period of one year.
InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer
Business Wire - Mon Feb 24, 7:03AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced appointment of Thomas R. Ulich, MD as Chief Scientific Officer, effective February 24, 2014.
OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Holdings Corp sends amended protocol to FDA and six cllinical sites for approval
M2 - Mon Jan 06, 5:43AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) reported on Friday the submission of the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair to the US Food and Drug Administration.
InVivo Sends Amended Protocol to FDA and Six Clinical Sites
Business Wire - Fri Jan 03, 2:18PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has sent to the United States Food and Drug Administration the revised protocol and related study documents for a clinical study to test the safety of its investigational scaffold device for spinal cord repair. The revised protocol includes all changes that were conditions of approval by the FDA. On Monday, it will send the revised protocol and related study documents to six sites in the United States so that they can now begin their Institutional Review Board submissions and finalize clinical study contracts with InVivo.
Novel Health Initiative for Walgreen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 5:20PM CST
Walgreen undertakes a novel initiative to help in the implementation of the Affordable Care Act.
InVivo Announces Regulatory and Clinical Promotions
Business Wire - Fri Dec 27, 8:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.
InVivo Therapeutics to Move Forward with Its First Clinical Trial After Receiving FDA Conditional Approval
Business Wire - Thu Dec 26, 1:00PM CST
InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the safety trial of its first investigational product, a degradable polymer scaffold for spinal cord injury. InVivo submitted these proposed changes to the FDA on November 21, 2013 and will follow the FDA's approval conditions in their entirety in a submission to the FDA next week.
InVivo Therapeutics Holdings Corp elects Mark Perrin as CEO
M2 - Tue Dec 24, 7:14AM CST
Biomaterials company InVivo Therapeutics Holdings Corp (Other OTC:NVIV) reported on Monday the election of Mark D Perrin as its chief executive officer.
InVivo Names Mark Perrin as Its New Chief Executive Officer
Business Wire - Mon Dec 23, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Mark D. Perrin as Chief Executive Officer, effective January 6, 2014. Upon his appointment, Mr. Perrin will also become a member of the Board of Directors.
OTC Daily Alert Stock Watch - InVivo Therapeutics Holdings Corp. (OTCQB: NVIV)
WorldStockWire - Wed Dec 18, 4:45AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
InVivo Therapeutics Appoints Steven McAllister as Interim CFO
Business Wire - Mon Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Interim Chief Financial Officer, effective December 31, 2013. He replaces Gregory Perry, who, as previously announced, will leave December 30, 2013 to join another local biotechnology company as its Chief Financial and Business Officer.
InVivo Therapeutics Announces Promotions in Technical Operations
Business Wire - Mon Dec 09, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that William D'Agostino has been promoted to Vice President, Manufacturing & Engineering and Robert Ham has been promoted to Senior Director, Quality. These promotions are effective January 1, 2014.
InVivo Therapeutics names Christopher McNulty as VP, Business Development
M2 - Tue Nov 19, 4:05AM CST
InVivo Therapeutics Holdings Corp (OTC:NVIV), a biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, announced on Monday the appointment of Christopher McNulty as vice president, Business Development.
InVivo Therapeutics Appoints Christopher McNulty as Vice President, Business Development
Business Wire - Mon Nov 18, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as Vice President, Business Development.
InVivo Therapeutics Lead Program on Track
Business Wire - Fri Nov 15, 10:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today confirmed that the company expects that the clinical trial of its first investigational product, a degradable polymer scaffold designed to promote healing following acute spinal cord injury, will be ready to enroll patients in the first quarter of 2014.
News and Updates on CTIX, CERP, NVIV and TRTC
ACCESSWIRE - Tue Nov 12, 12:31AM CST
News and updates on Cellceutix Corporation (OTC:CTIX), Cereplast Inc. (OTC:CERP), InVivo Therapeutics Holdings Corp. (OTC:NVIV) and Terra Tech Corp. (OTC:TRTC).
InVivo Therapeutics Reports Third Quarter 2013 Financial Results
Business Wire - Thu Nov 07, 3:14PM CST
InVivo Therapeutics Holdings Corp. (NVIV), a life sciences company focused on the development and commercialization of novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions, today reported financial results for the three and nine months ended September 30, 2013.
Small Cap Equity Reports on NVIV, SCRC and WDDD
ACCESSWIRE - Mon Oct 28, 1:02AM CDT
InVivo Therapeutics Holdings Corp. (OTC: NVIV), ScripsAmerica, Inc. (OTC: SCRC) and Worlds Inc. (OTC: WDDD) are small cap stocks in focus.
InVivo Therapeutics Holdings Corp names Dr Lou Vaickus interim CMO
M2 - Fri Oct 11, 10:35AM CDT
Drug delivery company InVivo Therapeutics Holdings Corp (OTC Markets:NVIV) revealed on Friday the election of Dr Lou Vaickus, MD as its interim chief medical officer for one year commencing 15 October 2013.
InVivo Therapeutics Appoints Lou Vaickus, MD as Interim Chief Medical Officer
Business Wire - Fri Oct 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Lou Vaickus, MD has been appointed as interim Chief Medical Officer (CMO), effective October 15, 2013, for a period of one year.
(0)
(0)